Advancing Vision Care: Comprehensive Analysis of the Thyroid Eye Disease Treatment Market to See Booming Growth 2024-2031 | Janssen Biotech, Inc., Kala Pharmaceuticals, Inc

Market Overview:

Thyroid eye disease, also known as Graves' ophthalmopathy, is an autoimmune disorder that causes inflammation of muscles and fatty tissues around the eyes. It leads to bulging of eyes, dryness and double vision. Medications like steroids, radiation therapy and surgery are used for treatment of thyroid eye disease.

Market Dynamics:

Increasing prevalence of thyroid disorders is a major factor driving growth of the thyroid eye disease treatment market. For instance, according to the American Thyroid Association, approximately 20 million Americans have some form of thyroid disease. Moreover, rising awareness about available treatment options and new product launches are also positively impacting the market growth. In 2020, Horizon Therapeutics launched TEPEZZA (teprotumumab-trbw) for treatment of thyroid eye disease which widened treatment options. However, high costs associated with specialized procedures and lack of awareness in underdeveloped regions can hinder the market growth.

Get an Exclusive Sample Copy of the Report at: - https://www.coherentmarketinsights.com/insight/request-sample/3538

Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, a detailed analysis of the competitive landscape, and product services of key players. Analysis of Thyroid Eye Disease Treatment companies, key tactics followed by Leading Key Players:

◘ Horizon Therapeutics plc.
◘ Bausch & Lomb Incorporated
◘ Pfizer Inc.
◘ Janssen Biotech Inc.
◘ Kala Pharmaceuticals Inc.
◘ Hi-Tech Pharmacal Co. Inc.
◘ others.

Growing Prevalence of Thyroid Disorders is Driving Increased Adoption of Thyroid Eye Disease Treatment

The increasing prevalence of thyroid disorders such as hyperthyroidism and hypothyroidism has been a key growth driver for the thyroid eye disease treatment market. According to estimates, approximately 10-20 million Americans currently suffer from thyroid disorders. Uncontrolled thyroid conditions can often lead to complications like thyroid eye disease in which the muscles and fatty tissues behind the eye become inflamed and swollen. With rising obesity and sedentary lifestyles fueling the incidence of thyroid issues, more patients are being diagnosed with thyroid eye disease each year requiring treatment.

Increased Adoption of Oral Medications for Thyroid Eye Disease Management

While steroids have traditionally formed the mainstay of thyroid eye disease treatment, oral immunosuppressants like steroids are now increasingly being used either alone or in combination owing to their several advantages over steroids. Oral medications offer greater convenience and compliance compared to intravenous administration. They also allow for outpatient treatment unlike steroids which often require inpatient hospitalization and monitoring. The preference for oral drugs has led pharmaceutical companies to invest more resources into developing novel oral drugs with improved efficacy and safety profiles. This is anticipated to give an added boost to market revenues over the coming years.

Cost of Treatment Poses a Significant Challenge

While the overall need for thyroid eye disease treatments is growing, high costs continue to restrict wider access and adoption. For example, the list prices of emerging biologic therapies approved for thyroid eye disease are upwards of $10,000 per month posing an affordability challenge for many patients as well as insurance companies and government payers. Even established drugs like oral steroids incur significant cumulative costs when treatment extends for several months. The expensive nature of treatment forces many patients to opt for minimalistic interventions or delay care. This cost barrier could hinder the thyroid eye disease treatment industry from realizing its full commercial potential.

Buy This Premium Report and Get Upto 25 % OFF: https://www.coherentmarketinsights.com/insight/buy-now/3538

Novel Therapies Present New Opportunities

With the limitations of current treatment options, there exists a sizeable opportunity for novel drug classes and therapies that can potentially overcome some of the drawbacks. For instance, targeted therapies like teprotumumab that selectively block the IGF-1R pathway being investigated for thyroid eye disease could emerge as breakthrough products with superior efficacy over glucocorticoids. Advancements in gene therapy and RNA interference also open possibilities for developing new cures. Non-drug modalities such as punctal plugs, tear neurostimulators present opportunities as well. The large unmet needs also mean lucrative prospects for developers of affordable generics and biosimilars in future.

Growing Acceptance of Combination Therapies as Standard of Care

Currently, the overall thyroid eye disease treatment approach involves medication, often immuno-suppression drugs like glucocorticoids, along with orbital radiotherapy and/or decompression surgery depending on severity. However, guidelines are now gravitating towards earlier introduction and duration of combination treatments instead of sequential single therapies. This recognizes synergistic benefits when different classes of drugs targeting divergent disease mechanisms are administered concurrently. As clinical evidence supporting superiority of dual therapies accrues, their adoption as first-line standard is likely to accelerate. It reflects a paradigm shift with considerable scope to further drive market revenues through a life-cycle approach rather than mono-therapies.

Segment Details Analysis

On the basis of drug type,

Steroids
Monoclonal Antibody
Others

On the basis of route of administration,

Oral
Intravenous
Topical
Others

On the basis of distribution channel,

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

The Study Objectives are:

A comprehensive insight into key players operating in the Thyroid Eye Disease Treatment Market and their corresponding data.
It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
Regional analysis, which includes insight into the dominant market and corresponding market share.
It also includes various socio-economic factors affecting the evolution of the market in the region.
The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Contents:

Market scenario 2024

Chapter 1: Introduction, Market Driving Force Product Objective of Study and Research Scope the Thyroid Eye Disease Treatment market
Chapter 2: Exclusive Summary - the basic information of the Thyroid Eye Disease Treatment Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends, and Challenges & Opportunities of the Thyroid Eye Disease Treatment
Chapter 4: Presenting the Thyroid Eye Disease Treatment Market Factor Analysis, Supply/Value Chain, PESTEL analysis, Market Entry, and Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User, and Region/Country 2024 - 2031
Chapter 6: Evaluating the leading manufacturers of the Thyroid Eye Disease Treatment market which consists of its Competitive Landscape, Peer Group Analysis, Market positioning & Company Profile
Chapter 7: To evaluate the market by segments, by countries, and by Manufacturers/Companies with revenue share and sales by key countries in these various regions (2024-2031)
Chapters 8 & 9: Displaying the Appendix, Methodology, and Data Source

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/3538

Key Questions Answered:

What is the market size and CAGR of the Thyroid Eye Disease Treatment Market during the forecast period?
How is the growing demand impacting the growth of Thyroid Eye Disease Treatment Market shares?
What is the growing demand of the Market during the forecast period?
Who are the leading vendors in the market and what are their market shares?
What is the impact of the COVID-19 pandemic on the APAC Thyroid Eye Disease Treatment Market?

Contact Us

Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States
Phone: US +12067016702 / UK +4402081334027
JAPAN:+81-50-5539-1737
INDIA:+91-848-285-0837
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.